Background Over a century ago, Virchow proposed that cancer represents a chronically inflamed, poorly healing wound. Normal wound healing is represented by a transitory phase of inflammation, followed by a pro-resolution phase, with prostaglandin (PGE2/PGD2)-induced ‘lipid class switching’ producing inflammation-quenching lipoxins (LXA4, LXB4). Objective We explored if lipid dysregulation in colorectal cancers (CRCs) is driven by a failure to resolve inflammation. Design We performed liquid chromatography and tandem mass spectrometry (LC–MS/MS) untargeted analysis of 40 human CRC and normal paired samples and targeted, quantitative analysis of 81 human CRC and normal paired samples. We integrated analysis of lipidomics, quantitative reverse transcription-PCR, large scale gene expression, and spatial transcriptomics with public scRNASEQ data to characterize pattern, expression and cellular localisation of genes that produce and modify lipid mediators. Results Targeted, quantitative LC–MS/MS demonstrated a marked imbalance of pro-inflammatory mediators, with a dearth of resolving lipid mediators. In tumours, we observed prominent over-expression of arachidonic acid derivatives, the genes encoding their synthetic enzymes and receptors, but poor expression of genes producing pro-resolving synthetic enzymes and resultant lipoxins (LXA4, LXB4) and associated receptors. These results indicate that CRC is the product of defective lipid class switching likely related to inadequate or ineffective levels of PGE2/PGD2. Conclusion We show that the lipidomic profile of CRC tumours exhibits a distinct pro-inflammatory bias with a deficiency of endogenous resolving mediators secondary to defective lipid class switching. These observations pave the way for ‘resolution medicine’, a novel therapeutic approach for inducing or providing resolvins to mitigate the chronic inflammation driving cancer growth and progression.
1 December 2020 in International Journal of Surgery
Circular staplers perform a critical function for creation of anastomoses in colorectal surgeries. Powered stapling systems allow for reduced force required by surgeons to fire the device and may provide advantages for creating a secure anastomosis. The objective of this study was to evaluate the clinical performance of a novel circular powered stapler in a post-market setting, during left-sided colectomy procedures. Consecutive subjects underwent left-sided colorectal resections that included anastomosis performed with the ECHELON CIRCULAR™ Powered Stapler (ECP). The primary endpoint was the frequency in which a stapler performance issue was observed. Secondary endpoints included evaluation of ease of use of the device via a surgeon satisfaction questionnaire, and monitoring/recording of procedure-related adverse events (AEs). A total of 168 anastomoses were performed with the ECP. Surgical approaches included robotic-assisted (n= 74, 44.0%), laparoscopic (n=71, 42.3%), open (n=20, 11.9%), and hand-assisted minimally invasive (n=3, 1.8%) procedures. There were 22 occurrences of device performance issues in 20 (11.9%) subjects during surgery. No positive intraoperative leak tests were observed, and only 1 issue was related to a procedure-related AE or surgical complication, which was an instance of incomplete surgical donut necessitating re-anastomosis. Postoperative anastomotic leaks were experienced in 4 (2.4%) subjects. Clavien-Dindo classification of all AEs indicated that 92.0% were Grades I or II. Participating surgeons rated the ECP as easier to use compared to previously used manual circular staplers in 85.7% of procedures. The circular powered stapler exhibited few clinically relevant performance issues, an overall favorable safety profile, and ease of use for creation of left-sided colon anastomoses.
Background/Objectives: Nonoperative management (NOM) of patients with locally advanced rectal cancer (LARC) who achieve a complete clinical response (cCR) to total neoadjuvant therapy (TNT) has been shown to be oncologically safe and is an attractive treatment option for patients. However, identifying responders to TNT that may benefit from nonoperative management is clinically challenging. Circulating tumor DNA (ctDNA) testing has shown promise in detecting minimal residual disease but has not yet been studied extensively within this clinical context. Methods: This is a single-institution retrospective case series study of LARC patients treated with TNT from 2019 to 2023 who underwent ctDNA testing as an adjunct to standard clinical response assessments. Results: A total of 28 patients had ctDNA testing as part of their response assessments after TNT. In total, 9 patients had positive ctDNA, and 19 patients had negative ctDNA during surveillance. Baseline characteristics of these two groups were not different. In this study, 6/9 (67%) patients who had positive ctDNA required surgery for residual rectal cancer, whereas only 4/19 (21%) patients who had negative ctDNA required surgery (p = 0.035). Conclusions: ctDNA testing has the potential to detect MRD in LARC patients treated with TNT.
15 March 2026 in Journal of Minimally Invasive Surgery
William N. Doyle Jr, Ashley J. Alden, Jetsen A. Rodriguez-Silva, Jin Kim, Sharan Poonja, Melissa A. Kendall, Kaylee Smith, Carolina Martinez, Allen Chudzinski, Lisa Moudgill, Paul Cavallaro, Jorge E. Marcet, Robert D. Bennett. Journal of Minimally Invasive Surgery 2026;29:22-30. https://doi.org/10.7602/jmis.2026.29.1.22
4 February 2026 in International Journal of Surgery Case Reports
Introduction: Tailgut cysts, or retrorectal cystic hamartomas, are uncommon developmental lesions found in the theoretical space between the rectum and the sacrum. Frequently asymptomatic and incidentally detected, they occur predominantly in women. Compression of nearby structures may cause perineal and back pain and even obstructed labor. Case Report: We report a case of a 50-year-old man with prior coccygeal fracture who presented with dull perineal pain, worsened by prolonged sitting. MRI revealed a cystic mass, and surgical excision was performed via a posterior perineal approach. Postoperative recovery was uneventful apart from surgery-related increased perineal pain. Pathology demonstrated a retrorectal cystic hamartoma. Discussion: Tailgut cysts are thought to originate from the embryonic tail, which normally regresses by the eighth week of gestation. MRI is the preferred imaging modality, with cysts appearing hypointense on T1 and hyperintense on T2 images. Solid components or irregular cyst walls on imaging may suggest malignancy. Preoperative biopsy carries risks of hemorrhage, infection, and tract seeding. In purely cystic lesions, complete surgical resection without biopsy is preferred. A perineal approach is recommended for small lesions below S3, while abdominal and abdominoperineal approaches are needed for larger lesions and those superior to S3. Routine coccygectomy was previously thought necessary to prevent recurrence but is now understood to be avoidable unless needed for exposure or the cyst is adherent. Malignant transformation occurs in up to 27% of cases, with recurrence up to 16%. Complete excision is essential to prevent recurrence and obtain a definitive diagnosis. Conclusion: Tailgut cysts, the most common retrorectal tumors, are often asymptomatic. MRI is the preferred imaging modality. Complete surgical resection is crucial to prevent malignancy and recurrence. The role of preoperative biopsy is controversial, and routine coccygectomy is no longer recommended.